• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Healthcare·HAEK.DE
Share

Haemato AG Stocks

€ 0Last Updated 23.03.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

€ 129.04M

€ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European imported drugs and medical products; and manufactures and distributes its generic drugs. It provides pharmaceuticals in the areas of oncology, HIV, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic medicine, as well as cosmetic products. The company also develops and markets medical devices and medical technology products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors, clinics, and medical laboratories. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is undervalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 23:18

Visa will cut 7% of its workforce. One of the reasons is the implementation of AI

28.07.2026 22:21

Apple's market capitalization reached $5 trillion for the first time

28.07.2026 22:17

The EU is preparing a record-breaking package of sanctions against more than 1,600 Russian companies — media reports

28.07.2026 22:14

Boeing's loss was worse than expected. Why are its shares rising?

28.07.2026 21:58

U.S. senators have agreed on “severe sanctions” against Russia. What happens next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026